Swiss - Delayed Quote CHF
Relief Therapeutics Holding SA (RLF.SW)
2.2700
+0.0050
+(0.22%)
At close: June 13 at 5:31:20 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
8,417
8,417
6,033
6,081
3,321
Cost of Revenue
2,575
2,575
1,736
1,250
19,774
Gross Profit
5,842
5,842
4,297
4,831
-16,453
Operating Expense
13,748
13,748
24,075
40,305
18,158
Operating Income
-7,906
-7,906
-19,778
-35,474
-34,611
Net Non Operating Interest Income Expense
-79
-79
-791
-1,902
-1,276
Other Income Expense
-11,371
-11,371
-91,115
-16,940
362
Pretax Income
-19,356
-19,356
-111,684
-54,316
-35,525
Tax Provision
-2,237
-2,237
-13,503
-3,526
-820
Net Income Common Stockholders
-17,119
-17,119
-98,181
-50,790
-34,705
Diluted NI Available to Com Stockholders
-17,119
-17,119
-98,181
-50,790
-34,705
Basic EPS
-1.36
-1.36
-8.35
-4.80
-4.00
Diluted EPS
-1.36
-1.36
-8.35
-4.80
-4.00
Basic Average Shares
12,540.4390
12,540.4390
11,752.4660
10,570.2810
8,982.6730
Diluted Average Shares
12,540.4390
12,540.4390
11,752.4660
10,570.2810
8,982.6730
Total Operating Income as Reported
-18,885
-18,885
-110,828
-52,040
-34,306
Total Expenses
16,323
16,323
25,811
41,555
37,932
Net Income from Continuing & Discontinued Operation
-17,119
-17,119
-98,181
-50,790
-34,705
Normalized Income
-6,867.5881
-6,867.5881
-18,025.8713
-34,630.8206
-35,040.0828
Interest Income
188
188
93
18
40
Interest Expense
215
215
330
1,434
797
Net Interest Income
-79
-79
-791
-1,902
-1,276
EBIT
-19,141
-19,141
-111,354
-52,882
-34,728
EBITDA
-16,580
-16,580
-108,036
-49,022
-32,692
Reconciled Cost of Revenue
2,575
2,575
1,736
1,250
19,774
Reconciled Depreciation
2,561
2,561
3,318
3,860
2,036
Net Income from Continuing Operation Net Minority Interest
-17,119
-17,119
-98,181
-50,790
-34,705
Total Unusual Items Excluding Goodwill
-11,591
-11,591
-91,179
-17,281
343
Total Unusual Items
-11,591
-11,591
-91,179
-17,281
343
Normalized EBITDA
-4,989
-4,989
-16,857
-31,741
-33,035
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0001
0
Tax Effect of Unusual Items
-1,339.5881
-1,339.5881
-11,023.8713
-1,121.8206
7.9172
12/31/2021 - 8/26/2009
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SANN.SW Santhera Pharmaceuticals Holding AG
12.20
-3.94%
NWRN.SW Newron Pharmaceuticals S.p.A.
7.25
-1.23%
MOLN.SW Molecular Partners AG
3.1150
-0.80%
IDIA.SW Idorsia Ltd
2.0300
-2.17%
HALB Halberd Corporation
0.0025
+4.17%
0M4.BE Mersana Therapeutics Inc
0.3149
+1.55%
SMZ1.SG Sino Biopharmaceutical Limited
0.6012
-1.05%
ALOPM.PA Oncodesign Precision Medicine Société anonyme
0.3100
-1.27%
IDIAz.XC
VSC.F 4SC AG
1.0300
-2.37%